

IN THE CLAIMS:

1-3 (Previously canceled).

4. (Currently amended) An isolated multimeric Mts1 protein complex, comprising at least three Mts1 protein molecules of an Mts1 protein.

5. (Original) The isolated multimeric Mts1 protein complex of claim 4, having a Mw in the range of about 30 kD to about 200 kD.

6. (Currently amended) The isolated multimeric Mts1 protein complex of claim 4, wherein the said Mts1 protein molecule is a wild type Mts1 protein.

7. (Currently amended) The An isolated multimeric Mts1 protein complex of claim 4, wherein the Mts1 protein molecule is comprising at least three molecules of Mts1-del75.

8. (Currently amended) The isolated multimeric Mts1 protein complex of claim 4, wherein the said Mts1 protein molecule is of a mammalian origin.

9. (Previously canceled).

10. (Original) A pharmaceutical composition comprising the isolated complex of claim 4, and a pharmaceutically acceptable carrier.

11. (Previously amended) The pharmaceutical composition of claim 10, wherein said pharmaceutically acceptable carrier is liquid, semi-solid, or solid.

12. (Previously amended) The pharmaceutical composition of claim 10, further comprising a neurotropic factor.

13. (Original) The pharmaceutical composition of claim 12, wherein said neurotropic factor is selected from the group consisting of bFGF, aFGF, CNTF, NGF, BDNF, GDNF, NT3, NT4/5, IGF-1 and IGF-II.

14-25 (Currently canceled).

26. (New) The isolated multimeric Mts1 protein complex of claim 4, wherein said Mts-1 protein is a human Mts-1 protein.

27. (New) The isolated multimeric Mts1 protein complex of claim 26, wherein said human Mts-1 protein comprises the sequence as set forth in SEQ ID NO: 1.

28. (New) The isolated multimeric Mts1 protein complex of claim 4, wherein said Mts-1 protein comprises the sequence as set forth in SEQ ID NO: 2.

29. (New) An isolated multimeric Mts1 protein complex, comprising at least three molecules of human Mts1-del75.